WS
AVXL icon

Wedbush Securities’s Anavex Life Sciences AVXL Stock Holding History

Wedbush Securities’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-14,000
Closed -$43K – 989
2019
Q1 		$43K Buy
+14,000
New +$33.4K ﹤0.01% 899

Other funds holding AVXL

PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Wedbush Securities's AVXL Position: Q2 2019 in Review

Wedbush Securities sold out of Anavex Life Sciences (AVXL) in Q2 2019, closing a stake of 14,000 shares — an estimated $43K sold.

Wedbush Securities first reported a position in AVXL in Q1 2019 and held it in 1 quarter. The position peaked at $43K in Q1 2019. 59 funds tracked by Wall St. Rank hold AVXL as of Q2 2019.

  • Wedbush Securities reported no remaining Anavex Life Sciences position as of Q2 2019 after selling out during the quarter.
  • Wedbush Securities sold 14,000 Anavex Life Sciences shares in Q2 2019, an estimated $43K.
  • Wedbush Securities first reported a position in Anavex Life Sciences in Q1 2019 and held it in 1 quarter.
  • Wedbush Securities's Anavex Life Sciences position peaked at $43K in Q1 2019.
  • 59 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2019.

Based on Wedbush Securities's 13F filing for Q2 2019, filed 1 Aug 2019.